A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Inhalation Powder in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 03 Dec 2025
At a glance
- Drugs TQC 3721 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 03 Dec 2025 New trial record